Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

287 trials

NCT07300553
Recruiting
Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease
Phase 2 · France · 1 site
Registry update: 12 Mar 2026
NCT07302360
Recruiting
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
Not applicable · China · 11 sites
Registry update: 3 Nov 2026
NCT07265570
Recruiting
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
Phase 2 · China · 28 sites
Registry update: 29 Oct 2026
NCT07235904
Recruiting
Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis
Phase 4 · Germany · 22 sites
Registry update: 16 Dec 2025
NCT07216014
Recruiting
Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety
Phase 4 · China · 1 site
Registry update: 24 Apr 2026
NCT07237516
Recruiting
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Not applicable · United States · 11 sites
Registry update: 5 Aug 2026
NCT07593352
Recruiting
Renal Dysfunction in Patients With Inflammatory Bowel Disease and the General Population (NEPHRO-IBD)
Not applicable · Poland · 1 site
Registry update: 18 May 2026
NCT07242248
Recruiting
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
Not applicable · United Kingdom · 1 site
Registry update: 3 Nov 2026
NCT06693310
Recruiting
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
Not applicable · United States · 1 site
Registry update: 19 Oct 2026
NCT07224113
Recruiting
Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
Not applicable · United States · 1 site
Registry update: 16 Jul 2026
NCT07186101
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Phase 2 · Austria, Brazil, Canada, China, Germany, Denmark, Spain, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Romania, United States · 147 sites
Registry update: 4 Nov 2026
NCT07223424
Recruiting
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Phase 2 · United States · 1 site
Registry update: 16 Apr 2026
NCT07338565
Recruiting
Magnesium in Gastrointestinal Disease
Not applicable · Denmark · 1 site
Registry update: 14 Jan 2026
NCT07198113
Recruiting
COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
Not applicable · United States · 4 sites
Registry update: 17 Apr 2026
NCT06405087
Recruiting
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Phase 3 · Belgium, Bulgaria, Switzerland, Denmark, Spain, Ireland, Italy, Japan, South Korea, Netherlands, Poland, Portugal, Romania, Serbia, Taiwan, United States · 54 sites
Registry update: 9 Oct 2026
NCT07195123
Recruiting
Evaluation of the SMART IBD App in Pediatric IBD
Not applicable · United States · 1 site
Registry update: 21 Nov 2025
NCT07229950
Recruiting
A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
Phase 2 · China · 1 site
Registry update: 2 Jun 2026
NCT07115862
Recruiting
Effects of Pomegranate Juice on Ulcerative Colitis
Not applicable · United States · 2 sites
Registry update: 9 Dec 2025
NCT07136116
Recruiting
Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
Not applicable · Japan · 29 sites
Registry update: 14 Aug 2026
NCT07303686
Recruiting
De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis
Phase 4 · Canada · 1 site
Registry update: 26 Dec 2025

Ordered by registry start date. Freshness and sponsorship never change the order.